SC
NKTR icon

Sophrosyne Capital’s Nektar Therapeutics NKTR Stock Holding History

Sophrosyne Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-4,013
Closed -$728K – 73
2014
Q1 		$728K Buy
+4,013
New +$794K 0.64% 33
2013
Q4 		– Sell
-9,140
Closed -$1.43M – 73
2013
Q3 		$1.43M Buy
+9,140
New +$1.69M 0.95% 30

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Sophrosyne Capital's NKTR Position: Q2 2014 in Review

Sophrosyne Capital sold out of Nektar Therapeutics (NKTR) in Q2 2014, closing a stake of 4,013 shares — an estimated $728K sold.

Sophrosyne Capital first reported a position in NKTR in Q3 2013 and held it in 2 quarters. The position peaked at $1.43M in Q3 2013. 144 funds tracked by Wall St. Rank hold NKTR as of Q2 2014.

  • Sophrosyne Capital reported no remaining Nektar Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Sophrosyne Capital sold 4,013 Nektar Therapeutics shares in Q2 2014, an estimated $728K.
  • Sophrosyne Capital first reported a position in Nektar Therapeutics in Q3 2013 and held it in 2 quarters.
  • Sophrosyne Capital's Nektar Therapeutics position peaked at $1.43M in Q3 2013.
  • 144 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2014.

Based on Sophrosyne Capital's 13F filing for Q2 2014, filed 14 Aug 2014.